Alzamend converts Series B preferred into 300k shares

Alzamend Neuro, Inc. reported that between September 17 and September 25, 2025, it issued 300,000 shares of common stock upon the conversion of an aggregate of 696 shares of Series B Convertible Preferred Stock.

Rhea-AI Filing Summary

Alzamend Neuro, Inc. reported that between September 17 and September 25, 2025, it issued 300,000 shares of common stock upon the conversion of an aggregate of 696 shares of Series B Convertible Preferred Stock. These common shares were issued in a private transaction relying on an exemption from registration under Section 4(a)(2) of the Securities Act.

After these conversions, Alzamend Neuro had 3,439,861 shares of common stock outstanding as of September 25, 2025, giving investors an updated view of the company’s equity base and recent preferred-to-common share activity.

8-K Event Classification

2 items: 3.02, 9.01

2 items

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alzamend Neuro (ALZN) disclose in this report?

Alzamend Neuro disclosed that it issued 300,000 shares of common stock upon the conversion of 696 shares of Series B Convertible Preferred Stock during the period from September 17 to September 25, 2025.

How many Alzamend Neuro (ALZN) common shares are now outstanding?

As of September 25, 2025, Alzamend Neuro had 3,439,861 shares of common stock outstanding following the preferred stock conversions.

What type of securities were converted by Alzamend Neuro (ALZN)?

Alzamend Neuro converted 696 shares of Series B Convertible Preferred Stock into 300,000 shares of common stock, $0.0001 par value per share.

Was the Alzamend Neuro (ALZN) common stock issuance registered with the SEC?

No. The 300,000 common shares were issued in reliance on an exemption from SEC registration under Section 4(a)(2) of the Securities Act.

Does this Alzamend Neuro (ALZN) filing involve a public offering of new shares?

The filing describes the issuance of 300,000 common shares upon conversion of preferred stock in a transaction exempt from registration; it does not describe a public offering.

What is the par value of Alzamend Neuro (ALZN) common stock?

Alzamend Neuro’s common stock has a par value of $0.0001 per share, as noted in the description of the newly issued shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/25/2025 - 04:30 PM Learn about SEC filing dates

false 0001677077 0001677077 2025-09-25 2025-09-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

___________________________________________________________________

Date of Report (Date of earliest event reported):  September 25, 2025

ALZAMEND NEURO, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-40483	81-1822909
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326

(Address of principal executive offices) (Zip Code)

(844) 722-6333

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		ALZN		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 3.02 Unregistered Sales of Equity Securities.

Between September 17, 2025 and September 25, 2025, Alzamend Neuro, Inc. (the “Company”) issued an aggregate of 300,000 shares of common stock, par value $0.0001 per share (“Common Stock”) upon conversion of an aggregate of 696 shares of Series B Convertible Preferred Stock. The shares of Common Stock were issued in reliance upon exemption from the registration requirements under Section 4(a)(2) under the Securities Act.

As of September 25, 2025, the Company had 3,439,861 shares of Common Stock outstanding.

Item 9.01 Financial Statements And Exhibits

(d) Exhibits:

Exhibit No.		Description
101		Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALZAMEND NEURO, INC.
Dated: September 25, 2025	/s/ Henry Nisser Henry Nisser Executive Vice President and General Counsel

3